Acid hydrolysis of jaboticaba (Myrciaria jaboticaba) peel and seed powder increases urolithin excretion in a cross-over clinical trial with normoweight subjects.

Den randomiserade kliniska crossover-studien undersökte 23 normalviktiga vuxna efter en engångsdos på 3 g i kapsel med pulver från skal och frön av jaboticaba. Deltagarna fick antingen icke-hydrolyserat pulver eller syrahydrolyserat pulver, med en 14-dagars uppehållsperiod mellan behandlingarna. Urine was collected for up to 72 hours to assess urolithin metabolites.

The hydrolysed preparation contained 57.1 mg free ellagic acid, compared with 17.8 mg in the non-hydrolysed preparation, a 3.2-fold difference. Glucuronidated urolithins made up 85% of total urinary excretion. Urolitin A 3/8-glucuronide was the main metabolite, accounting for 54% of total excretion after non-hydrolysed powder and 57% after hydrolysed powder. Urolithins were detected in urine 8 hours after hydrolysed powder. Time to peak excretion did not differ materially, at 29.2 hours for non-hydrolysed powder and 28.3 hours for hydrolysed powder.

Acid hydrolysis increased total urolithin excretion by up to 69% from 0 to 48 hours and by 50% over 72 hours. This is evidence of altered absorption and microbial metabolism, not of a health benefit. It did not test a urolithin A supplement, physical function, mitochondrial function, disease outcomes or longevity.

Acid hydrolysis of jaboticaba peel and seeds increased urolithin production in normal-weight subjects, probably by increasing availability for microbial conversion.